Pozzi Chiara, Sarti Riccardo, Lo Cascio Antonino, Bonovas Stefanos, Tiraboschi Luca, Lizier Michela, Bertocchi Alice, Torrisi Rosalba, Fernandes Bethania, Colombo Piergiuseppe, Diana Pietro, Mazza Emilia Maria Cristina, Valeri Marina, Renne Salvatore Lorenzo, Cananzi Ferdinando Carlo Maria, Samà Laura, Bertuzzi Alexia, Tinterri Corrado, Lazzeri Massimo, Rescigno Maria
IRCCS Humanitas Research Hospital, via Manzoni 56, 20089 Rozzano, Milan, Italy.
Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20072 Pieve Emanuele, Milan, Italy.
EMBO Mol Med. 2025 Jul 21. doi: 10.1038/s44321-025-00277-5.
Identification of biomarkers for the hematogenous spreading of cancer cells is of paramount prognostic and therapeutic value. We showed that Plasmalemma Vesicle Associated Protein-1 (PV-1) serves as a marker of increased blood vessel permeability and is an independent predictor of colorectal cancer dissemination. This study investigates whether PV-1 can also act as a prognostic marker for distant metastases in other solid tumors. We analyzed samples from 134 patients: 30 luminal breast cancer (BC), 52 clear cell renal cell carcinoma (ccRCC), and obtained preliminary data from 52 soft tissue sarcomas (STS). A higher frequency of PV-1+ endothelial cells was significantly associated with metastatic progression in luminal BC and ccRCC. Moreover, the frequency of PV-1+ cells emerged as a significant prognostic factor for metastasis-free survival in both luminal BC and ccRCC. Further research is needed to validate PV-1's prognostic utility, as including it at diagnosis may change the management of these patients and should allow stratification for more aggressive therapies or for closer follow-ups to promptly intervene in case of metastases development.
识别癌细胞血行播散的生物标志物具有至关重要的预后和治疗价值。我们发现质膜囊泡相关蛋白-1（PV-1）可作为血管通透性增加的标志物，并且是结直肠癌播散的独立预测因子。本研究调查PV-1是否也可作为其他实体瘤远处转移的预后标志物。我们分析了134例患者的样本：30例管腔型乳腺癌（BC）、52例透明细胞肾细胞癌（ccRCC），并从52例软组织肉瘤（STS）中获得了初步数据。PV-1+内皮细胞的较高频率与管腔型BC和ccRCC的转移进展显著相关。此外，PV-1+细胞的频率成为管腔型BC和ccRCC无转移生存期的显著预后因素。需要进一步研究来验证PV-1的预后效用，因为在诊断时纳入该指标可能会改变这些患者的治疗管理，并且应该能够对更积极的治疗进行分层，或者对转移发生时进行更密切的随访以便及时干预。
